Pharmacokinetic approach for optimizing gentamicin use in neonates during the first week of life

Indian Journal of Pharmacology

Volumn 44, Issue 1, 2012, Pages 36-40

  Ali, Ahmed S ^a   FadulAllah Farouq, M ^a   Al Faify, Khalid A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Gentamicin; pharmacokinetics; preterm neonates; therapeutic drug monitoring

Indexed keywords

CREATININE; GENTAMICIN;

ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG USE; EXTREMELY LOW BIRTH WEIGHT; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN PERIOD; PROCESS OPTIMIZATION; SEPSIS;

EID: 84856383126     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.91864     Document Type: Article

References (18)

1. Gomella TL, Cunningham MD, Eyal FG. Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs. 5 th ed. New York: Lange Medical Books; 2004.
2. Levene MI, Tudehope DI, Thearle MJ. Essentials of Neonatal Medicine. 3 rd ed. Oxford: Blackwell Science; 2000.
3. Thingvoll ES, Guillet R, Caserta M, Dicenzo R. Observational trial of a 48-hour genatmicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks' gestation. J Pediatr 2008;153:530-4.
4. Darmstadt GL, Miller-Bell M, Batra M, Law P, Law K. Extended-interval dosing of genatmicin for treatment of neonatal sepsis in developed and developing countries. J Health Popul Nutr 2008;26:163-82.
5. Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 2009;48:71-88.
6. Testa M, Fanos V, Martinelli V, Mussap M, Zompo M. Therapeutic drug monitoring of genatmicin in neonatal intensive care unit: Experience in 68 newborns. J Chemother 2007;19 Suppl 2:39-41.
7. Zaske D, Shikoma L, Tholl D. Aminoglycosides. In: Taylor W, Diers CM, editors. A Textbook for Theclinical Application of Therapeutic Drug Monitoring. Irving: Abbott Laboratories; 1986. p. 285-320.
8. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985;106:522-6. (Pubitemid 15140671)
9. Nestaas E, Bangstad HJ, Sandvik L, Wathne KO. Aminoglycoside extended interval dosing in neonates is safe and effective: A meta-analysis. Arch Dis Child 2005;90:F294-300. (Pubitemid 40933389)
10. Murphy J. Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates. Am J Health Syst Pharm 2005;62:823-7. (Pubitemid 40547366)
11. Locksmith G, Chin A, Vu T, Shattuck K, Hankins G. High compared with standard genta dosing for chorioamnionitis: A comparison of maternal and fetal serum drug levels. Obstet Gynecol 2005;105:473-9. (Pubitemid 40271208)
12. Vervelde ML, Rademaker CM, Krediet TG, Fleer A, Van Asten P, Van Dijk A. Population pharmacokinetics of genta in preterm neonates: Evaluation of a once-daily dosage regimen. Ther Drug Monit 1999;21:514-9. (Pubitemid 29468317)
13. Stolk LM, Degraeuwe PL, Nieman FH, De Wolf Mc, De Boer A. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of genta in neonates. Ther Drug Monit 2002;24:527-31. (Pubitemid 34857907)
14. Brunton LL, Lazo JS, Parker KL. The pharmacological basis of therapeutics. In: Goodman, Gilmans, editors. 11 th ed. New York: McGraw-Hill; 2006.
15. Anderson B, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009;24:25-36.
16. Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005;59:54-61. (Pubitemid 40040096)
17. Rocha MJ, Almeida AM, Afonso E, Martins V, Santos J, Leitão F, et al. The kinetic profile of genta in premature neonates. J Pharm Pharmacol 2000;52:1091-7.
18. Veltkamp SA, Westrman E, Sprij AJ, Sum BL, Touw DJ. Genta in preterm neonates: An extended interval dosing scuduale. Eur J Hosp Pharm Sci 2007;13:92-7.